Positive pre-clinical data has been announced by the pharmaceutical company Reata, providing more support for the rationale to test their drug, omaveloxolone, in neurodegenerative conditions such as Friedreich’s ataxia. Read the press release here. This drug is the same as the one currently in trials around the world including at the London Ataxia Centre. See here for more information about taking part.
Posted on 26/03/2018